Relating to the manufacture, sale, and distribution of products developed using mRNA material in the prevention or treatment of a communicable disease.
Impact
If passed, SB 1983 would have a notable impact on the state's healthcare landscape, particularly regarding products that utilize mRNA technology. With the recent success of mRNA vaccines, there is concern about how this bill might affect future innovations in vaccine development and therapies that use similar technology. By restricting the manufacture and distribution of such products, this legislation may potentially hinder research and development efforts within Texas, which could lead to a lag in the state's competitive position in the biotechnology sector.
Summary
Senate Bill 1983 focuses on the manufacture, sale, and distribution of products developed using messenger ribonucleic acid (mRNA) material aimed at preventing or treating communicable diseases. The bill explicitly prohibits any person or entity from engaging in these activities related to mRNA-based products. This reflects a significant regulatory approach toward biomedical products employing advanced technologies such as mRNA, which has been pivotal in recent vaccine developments.
Contention
The bill is likely to spark debate among healthcare professionals, legislators, and the biotechnology industry. Proponents may argue that the bill protects public health and safety by regulating emerging technologies. However, critics may contend that such restrictions could stifle innovation and limit access to potentially life-saving therapies developed through mRNA. As the implications for public health and economic growth are weighed, discussions around this bill will likely highlight the balance between safety, innovation, and regulation.
Identical
Relating to the manufacture, sale, and distribution of products developed using mRNA material in the prevention or treatment of a communicable disease.
Relating to the manufacture, sale, and distribution of products developed using mRNA material in the prevention or treatment of a communicable disease.
Relating to county and hospital district disease control pilot programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.
A bill for an act eliminating provisions relating to raw milk, including the production of raw milk at certain dairies, the manufacture of products using raw milk, and the labeling and distribution of raw milk and manufactured products.
Relating to infection prevention and control programs and other communicable diseases measures at certain long-term care facilities; authorizing an administrative penalty.
Prohibits the sale or distribution of products containing intentionally added PFAS and authorized the DNR to obtain information on the products and prosecute manufacturers for violations